Compare Stocks: ANIX, ZURA, KYTX, and ARCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.90 -0.3%	$3.11	$2.32 ▼ $5.46	$101.16M	0.47	356,134 shs	217,874 shs
ARCT Arcturus Therapeutics	$13.74 +6.8%	$12.75	$5.50 ▼ $24.17	$365.80M	2.48	821,257 shs	675,624 shs
KYTX Kyverna Therapeutics	$6.39 +3.4%	$7.61	$5.96 ▼ $13.67	$382.19M	2.06	996,369 shs	876,393 shs
ZURA Zura Bio	$4.00 -3.1%	$5.19	$3.15 ▼ $7.44	$395.77M	0.01	2.08 million shs	1.71 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-0.34%	-1.69%	+2.47%	-5.23%	-34.68%
ARCT Arcturus Therapeutics	+6.76%	+5.45%	-6.78%	+97.13%	-35.19%
KYTX Kyverna Therapeutics	+3.40%	+2.73%	-16.36%	-24.65%	-11.00%
ZURA Zura Bio	-3.15%	-2.68%	-29.95%	-21.72%	-7.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.90 -0.3%	$3.11	$2.32 ▼ $5.46	$101.16M	0.47	356,134 shs	217,874 shs
ARCT Arcturus Therapeutics	$13.74 +6.8%	$12.75	$5.50 ▼ $24.17	$365.80M	2.48	821,257 shs	675,624 shs
KYTX Kyverna Therapeutics	$6.39 +3.4%	$7.61	$5.96 ▼ $13.67	$382.19M	2.06	996,369 shs	876,393 shs
ZURA Zura Bio	$4.00 -3.1%	$5.19	$3.15 ▼ $7.44	$395.77M	0.01	2.08 million shs	1.71 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-0.34%	-1.69%	+2.47%	-5.23%	-34.68%
ARCT Arcturus Therapeutics	+6.76%	+5.45%	-6.78%	+97.13%	-35.19%
KYTX Kyverna Therapeutics	+3.40%	+2.73%	-16.36%	-24.65%	-11.00%
ZURA Zura Bio	-3.15%	-2.68%	-29.95%	-21.72%	-7.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.40	Hold	$8.00	175.86% Upside
ARCT Arcturus Therapeutics	2.67	Moderate Buy	$22.00	60.12% Upside
KYTX Kyverna Therapeutics	2.86	Moderate Buy	$29.00	353.83% Upside
ZURA Zura Bio	2.86	Moderate Buy	$17.00	325.00% Upside

Current Analyst Ratings Breakdown

Latest ANIX, ZURA, KYTX, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $19.00
10/6/2026	ANIX Anixa Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/2/2026	ZURA Zura Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/25/2026	KYTX Kyverna Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/25/2026	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/25/2026	KYTX Kyverna Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/24/2026	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$23.00 ➝ $20.00
9/24/2026	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00 ➝ $20.00
9/23/2026	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	480.02	N/A	N/A	$0.42 per share	6.90
ARCT Arcturus Therapeutics	$18.72M	20.86	N/A	N/A	$7.53 per share	1.82
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.32	N/A	N/A	N/A	N/A	-76.59%	-67.80%	N/A
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
ZURA Zura Bio	-$99.35M	-$1.13	N/A	N/A	N/A	N/A	-56.13%	-50.15%	11/12/2026 (Estimated)

Latest ANIX, ZURA, KYTX, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.0818	-$0.08	+$0.0018	-$0.08	N/A	N/A
8/11/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/11/2026	Q2 2026	ZURA Zura Bio	-$0.1913	-$0.21	-$0.0187	-$0.21	N/A	N/A
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	5.20%	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.55	8.54
ARCT Arcturus Therapeutics	N/A	5.88	5.88
KYTX Kyverna Therapeutics	0.15	9.06	9.06
ZURA Zura Bio	N/A	12.90	12.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
ARCT Arcturus Therapeutics	94.54%
KYTX Kyverna Therapeutics	18.08%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
ARCT Arcturus Therapeutics	17.80%
KYTX Kyverna Therapeutics	17.60%
ZURA Zura Bio	12.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	4	34.76 million	25.59 million	Optionable
ARCT Arcturus Therapeutics	111	28.42 million	23.36 million	Optionable
KYTX Kyverna Therapeutics	149	61.84 million	50.96 million	Optionable
ZURA Zura Bio	40	95.83 million	83.98 million	Optionable

ANIX, ZURA, KYTX, and ARCT Headlines

Recent News About These Companies

Analysts Are Bullish on These Healthcare Stocks: Zura Bio (ZURA), Alphatec Holdings (ATEC)

October 9 at 11:00 PM | theglobeandmail.com

Piper Sandler keeps Buy rating for Zura Bio stock

October 8 at 8:05 PM | ad-hoc-news.deA

This biotech stock is a top pick at Guggenheim

October 7 at 8:45 AM | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Stock Has Average Target Price of $17.00

October 6, 2026 | marketbeat.com

Guggenheim reiterates Buy rating for Zura Bio stock

October 5, 2026 | ad-hoc-news.deA

Zura Bio stock heads into Piper Sandler meeting with losses widening

October 4, 2026 | ad-hoc-news.deA

Zura Bio (NASDAQ:ZURA) Shares Down 0.7% - Here's What Happened

October 3, 2026 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Stock Price Down 0.7% - Here's What Happened

October 3, 2026 | marketbeat.com

Zura Bio stock enters a key trial data phase

September 29, 2026 | ad-hoc-news.deA

Zura Bio stock extends multi-month rally on strong pipeline expectations

September 20, 2026 | ad-hoc-news.deA

Zura Bio Limited Class A Ordinary Shares

September 19, 2026 | livemint.com

Zura Bio Limited (ZURA) Latest Press Releases & Corporate News - Yahoo Finance

September 17, 2026 | finance.yahoo.com

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply

September 11, 2026 | finance.yahoo.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from Analysts

September 11, 2026 | marketbeat.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | businesswire.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026 | businesswire.com

Zura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, Predictions

July 27, 2026 | benzinga.com

William Blair Starts Zura Bio (ZURA) at Outperform

July 14, 2026 | uk.finance.yahoo.com

Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist

July 9, 2026 | businesswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)

July 9, 2026 | theglobeandmail.com

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX, ZURA, KYTX, and ARCT Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.90 -0.01 (-0.34%)

As of 10/9/2026 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Arcturus Therapeutics NASDAQ:ARCT

$13.74 +0.87 (+6.76%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$13.52 -0.22 (-1.56%)

As of 10/9/2026 07:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Kyverna Therapeutics NASDAQ:KYTX

$6.39 +0.21 (+3.40%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.51 +0.12 (+1.88%)

As of 10/9/2026 07:30 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Zura Bio NASDAQ:ZURA

$4.00 -0.13 (-3.15%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.11 +0.11 (+2.85%)

As of 10/9/2026 07:30 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, ZURA, KYTX, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, ZURA, KYTX, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, ZURA, KYTX, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX, ZURA, KYTX, and ARCT Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Arcturus Therapeutics NASDAQ:ARCT

Kyverna Therapeutics NASDAQ:KYTX

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, ZURA, KYTX, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, ZURA, KYTX, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, ZURA, KYTX, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX, ZURA, KYTX, and ARCT Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Arcturus Therapeutics NASDAQ:ARCT

Kyverna Therapeutics NASDAQ:KYTX

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools